The changes of cardiac energy metabolism with sodium-glucose transporter 2 inhibitor therapy
S Su, X Ji, T Li, Y Teng, B Wang, X Han… - Frontiers in …, 2023 - frontiersin.org
Background/aims To investigate the specific effects of s odium-glucose transporter 2
inhibitor (SGLT2i) on cardiac energy metabolism. Methods A systematic literature search …
inhibitor (SGLT2i) on cardiac energy metabolism. Methods A systematic literature search …
A multicentre, double‐blind, placebo‐controlled, randomized, parallel comparison, phase 3 trial to evaluate the efficacy and safety of pioglitazone add‐on therapy in …
S Lim, SH Lee, KW Min, CB Lee, SY Kim… - Diabetes, Obesity …, 2024 - Wiley Online Library
Aim To investigate the efficacy and safety of pioglitazone compared to placebo when added
to metformin plus dapagliflozin, a sodium‐glucose cotransporter‐2 (SGLT2) inhibitor, for …
to metformin plus dapagliflozin, a sodium‐glucose cotransporter‐2 (SGLT2) inhibitor, for …
The Effect of Canagliflozin on High‐Density Lipoprotein Cholesterol and Angiopoietin‐Like Protein 3 in Type 2 Diabetes Mellitus
S Liu, J Ke, X Feng, Z Wang, X Wang… - Journal of Diabetes …, 2024 - Wiley Online Library
Background. Diabetes mellitus is often accompanied by dyslipidemia. Sodium‐glucose
cotransporter‐2 (SGLT2) inhibitors, as a novel therapeutic agent for the treatment of type 2 …
cotransporter‐2 (SGLT2) inhibitors, as a novel therapeutic agent for the treatment of type 2 …
Ингибиторы натрий-глюкозных котранспортеров и мозг
КВ Антонова, ММ Танашян, ОВ Лагода… - FOCUS …, 2023 - endofocus.elpub.ru
Аннотация Сахарный диабет (СД) ассоциирован с повышенным риском инсульта и
когнитивных нарушений. Проблема профилактики церебральных нарушений при СД …
когнитивных нарушений. Проблема профилактики церебральных нарушений при СД …